Global Durvalumab Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
LPI (LP Information)' newest research report, the “Durvalumab Industry Forecast” looks at past sales and reviews total world Durvalumab sales in 2022, providing a comprehensive analysis by region and market sector of projected Durvalumab sales for 2023 through 2029. With Durvalumab sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Durvalumab industry.
This Insight Report provides a comprehensive analysis of the global Durvalumab landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Durvalumab portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Durvalumab market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Durvalumab and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Durvalumab.
The global Durvalumab market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Durvalumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Durvalumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Durvalumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Durvalumab players cover Medimmune (AstraZeneca). etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Durvalumab market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Durvalumab market?
What factors are driving Durvalumab market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Durvalumab market opportunities vary by end market size?
How does Durvalumab break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Durvalumab Industry Forecast” looks at past sales and reviews total world Durvalumab sales in 2022, providing a comprehensive analysis by region and market sector of projected Durvalumab sales for 2023 through 2029. With Durvalumab sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Durvalumab industry.
This Insight Report provides a comprehensive analysis of the global Durvalumab landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Durvalumab portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Durvalumab market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Durvalumab and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Durvalumab.
The global Durvalumab market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Durvalumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Durvalumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Durvalumab is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Durvalumab players cover Medimmune (AstraZeneca). etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Durvalumab market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- 2.4mL Injection
- 10mL Injection
- Locally Advanced Urothelial Carcinoma
- Metastatic Urothelial Carcinoma
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Medimmune (AstraZeneca)
What is the 10-year outlook for the global Durvalumab market?
What factors are driving Durvalumab market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Durvalumab market opportunities vary by end market size?
How does Durvalumab break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Durvalumab Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Durvalumab by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Durvalumab by Country/Region, 2018, 2022 & 2029
2.2 Durvalumab Segment by Type
2.2.1 2.4mL Injection
2.2.2 10mL Injection
2.3 Durvalumab Sales by Type
2.3.1 Global Durvalumab Sales Market Share by Type (2018-2023)
2.3.2 Global Durvalumab Revenue and Market Share by Type (2018-2023)
2.3.3 Global Durvalumab Sale Price by Type (2018-2023)
2.4 Durvalumab Segment by Application
2.4.1 Locally Advanced Urothelial Carcinoma
2.4.2 Metastatic Urothelial Carcinoma
2.4.3 Other
2.5 Durvalumab Sales by Application
2.5.1 Global Durvalumab Sale Market Share by Application (2018-2023)
2.5.2 Global Durvalumab Revenue and Market Share by Application (2018-2023)
2.5.3 Global Durvalumab Sale Price by Application (2018-2023)
3 GLOBAL DURVALUMAB BY COMPANY
3.1 Global Durvalumab Breakdown Data by Company
3.1.1 Global Durvalumab Annual Sales by Company (2018-2023)
3.1.2 Global Durvalumab Sales Market Share by Company (2018-2023)
3.2 Global Durvalumab Annual Revenue by Company (2018-2023)
3.2.1 Global Durvalumab Revenue by Company (2018-2023)
3.2.2 Global Durvalumab Revenue Market Share by Company (2018-2023)
3.3 Global Durvalumab Sale Price by Company
3.4 Key Manufacturers Durvalumab Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Durvalumab Product Location Distribution
3.4.2 Players Durvalumab Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR DURVALUMAB BY GEOGRAPHIC REGION
4.1 World Historic Durvalumab Market Size by Geographic Region (2018-2023)
4.1.1 Global Durvalumab Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Durvalumab Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Durvalumab Market Size by Country/Region (2018-2023)
4.2.1 Global Durvalumab Annual Sales by Country/Region (2018-2023)
4.2.2 Global Durvalumab Annual Revenue by Country/Region (2018-2023)
4.3 Americas Durvalumab Sales Growth
4.4 APAC Durvalumab Sales Growth
4.5 Europe Durvalumab Sales Growth
4.6 Middle East & Africa Durvalumab Sales Growth
5 AMERICAS
5.1 Americas Durvalumab Sales by Country
5.1.1 Americas Durvalumab Sales by Country (2018-2023)
5.1.2 Americas Durvalumab Revenue by Country (2018-2023)
5.2 Americas Durvalumab Sales by Type
5.3 Americas Durvalumab Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Durvalumab Sales by Region
6.1.1 APAC Durvalumab Sales by Region (2018-2023)
6.1.2 APAC Durvalumab Revenue by Region (2018-2023)
6.2 APAC Durvalumab Sales by Type
6.3 APAC Durvalumab Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Durvalumab by Country
7.1.1 Europe Durvalumab Sales by Country (2018-2023)
7.1.2 Europe Durvalumab Revenue by Country (2018-2023)
7.2 Europe Durvalumab Sales by Type
7.3 Europe Durvalumab Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Durvalumab by Country
8.1.1 Middle East & Africa Durvalumab Sales by Country (2018-2023)
8.1.2 Middle East & Africa Durvalumab Revenue by Country (2018-2023)
8.2 Middle East & Africa Durvalumab Sales by Type
8.3 Middle East & Africa Durvalumab Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Durvalumab
10.3 Manufacturing Process Analysis of Durvalumab
10.4 Industry Chain Structure of Durvalumab
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Durvalumab Distributors
11.3 Durvalumab Customer
12 WORLD FORECAST REVIEW FOR DURVALUMAB BY GEOGRAPHIC REGION
12.1 Global Durvalumab Market Size Forecast by Region
12.1.1 Global Durvalumab Forecast by Region (2024-2029)
12.1.2 Global Durvalumab Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Durvalumab Forecast by Type
12.7 Global Durvalumab Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Medimmune (AstraZeneca)
13.1.1 Medimmune (AstraZeneca) Company Information
13.1.2 Medimmune (AstraZeneca) Durvalumab Product Portfolios and Specifications
13.1.3 Medimmune (AstraZeneca) Durvalumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Medimmune (AstraZeneca) Main Business Overview
13.1.5 Medimmune (AstraZeneca) Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Durvalumab Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Durvalumab by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Durvalumab by Country/Region, 2018, 2022 & 2029
2.2 Durvalumab Segment by Type
2.2.1 2.4mL Injection
2.2.2 10mL Injection
2.3 Durvalumab Sales by Type
2.3.1 Global Durvalumab Sales Market Share by Type (2018-2023)
2.3.2 Global Durvalumab Revenue and Market Share by Type (2018-2023)
2.3.3 Global Durvalumab Sale Price by Type (2018-2023)
2.4 Durvalumab Segment by Application
2.4.1 Locally Advanced Urothelial Carcinoma
2.4.2 Metastatic Urothelial Carcinoma
2.4.3 Other
2.5 Durvalumab Sales by Application
2.5.1 Global Durvalumab Sale Market Share by Application (2018-2023)
2.5.2 Global Durvalumab Revenue and Market Share by Application (2018-2023)
2.5.3 Global Durvalumab Sale Price by Application (2018-2023)
3 GLOBAL DURVALUMAB BY COMPANY
3.1 Global Durvalumab Breakdown Data by Company
3.1.1 Global Durvalumab Annual Sales by Company (2018-2023)
3.1.2 Global Durvalumab Sales Market Share by Company (2018-2023)
3.2 Global Durvalumab Annual Revenue by Company (2018-2023)
3.2.1 Global Durvalumab Revenue by Company (2018-2023)
3.2.2 Global Durvalumab Revenue Market Share by Company (2018-2023)
3.3 Global Durvalumab Sale Price by Company
3.4 Key Manufacturers Durvalumab Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Durvalumab Product Location Distribution
3.4.2 Players Durvalumab Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR DURVALUMAB BY GEOGRAPHIC REGION
4.1 World Historic Durvalumab Market Size by Geographic Region (2018-2023)
4.1.1 Global Durvalumab Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Durvalumab Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Durvalumab Market Size by Country/Region (2018-2023)
4.2.1 Global Durvalumab Annual Sales by Country/Region (2018-2023)
4.2.2 Global Durvalumab Annual Revenue by Country/Region (2018-2023)
4.3 Americas Durvalumab Sales Growth
4.4 APAC Durvalumab Sales Growth
4.5 Europe Durvalumab Sales Growth
4.6 Middle East & Africa Durvalumab Sales Growth
5 AMERICAS
5.1 Americas Durvalumab Sales by Country
5.1.1 Americas Durvalumab Sales by Country (2018-2023)
5.1.2 Americas Durvalumab Revenue by Country (2018-2023)
5.2 Americas Durvalumab Sales by Type
5.3 Americas Durvalumab Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Durvalumab Sales by Region
6.1.1 APAC Durvalumab Sales by Region (2018-2023)
6.1.2 APAC Durvalumab Revenue by Region (2018-2023)
6.2 APAC Durvalumab Sales by Type
6.3 APAC Durvalumab Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Durvalumab by Country
7.1.1 Europe Durvalumab Sales by Country (2018-2023)
7.1.2 Europe Durvalumab Revenue by Country (2018-2023)
7.2 Europe Durvalumab Sales by Type
7.3 Europe Durvalumab Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Durvalumab by Country
8.1.1 Middle East & Africa Durvalumab Sales by Country (2018-2023)
8.1.2 Middle East & Africa Durvalumab Revenue by Country (2018-2023)
8.2 Middle East & Africa Durvalumab Sales by Type
8.3 Middle East & Africa Durvalumab Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Durvalumab
10.3 Manufacturing Process Analysis of Durvalumab
10.4 Industry Chain Structure of Durvalumab
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Durvalumab Distributors
11.3 Durvalumab Customer
12 WORLD FORECAST REVIEW FOR DURVALUMAB BY GEOGRAPHIC REGION
12.1 Global Durvalumab Market Size Forecast by Region
12.1.1 Global Durvalumab Forecast by Region (2024-2029)
12.1.2 Global Durvalumab Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Durvalumab Forecast by Type
12.7 Global Durvalumab Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Medimmune (AstraZeneca)
13.1.1 Medimmune (AstraZeneca) Company Information
13.1.2 Medimmune (AstraZeneca) Durvalumab Product Portfolios and Specifications
13.1.3 Medimmune (AstraZeneca) Durvalumab Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Medimmune (AstraZeneca) Main Business Overview
13.1.5 Medimmune (AstraZeneca) Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Durvalumab Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Durvalumab Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of 2.4mL Injection
Table 4. Major Players of 10mL Injection
Table 5. Global Durvalumab Sales by Type (2018-2023) & (K Pcs)
Table 6. Global Durvalumab Sales Market Share by Type (2018-2023)
Table 7. Global Durvalumab Revenue by Type (2018-2023) & ($ million)
Table 8. Global Durvalumab Revenue Market Share by Type (2018-2023)
Table 9. Global Durvalumab Sale Price by Type (2018-2023) & (USD/Pcs)
Table 10. Global Durvalumab Sales by Application (2018-2023) & (K Pcs)
Table 11. Global Durvalumab Sales Market Share by Application (2018-2023)
Table 12. Global Durvalumab Revenue by Application (2018-2023)
Table 13. Global Durvalumab Revenue Market Share by Application (2018-2023)
Table 14. Global Durvalumab Sale Price by Application (2018-2023) & (USD/Pcs)
Table 15. Global Durvalumab Sales by Company (2018-2023) & (K Pcs)
Table 16. Global Durvalumab Sales Market Share by Company (2018-2023)
Table 17. Global Durvalumab Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Durvalumab Revenue Market Share by Company (2018-2023)
Table 19. Global Durvalumab Sale Price by Company (2018-2023) & (USD/Pcs)
Table 20. Key Manufacturers Durvalumab Producing Area Distribution and Sales Area
Table 21. Players Durvalumab Products Offered
Table 22. Durvalumab Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Durvalumab Sales by Geographic Region (2018-2023) & (K Pcs)
Table 26. Global Durvalumab Sales Market Share Geographic Region (2018-2023)
Table 27. Global Durvalumab Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Durvalumab Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Durvalumab Sales by Country/Region (2018-2023) & (K Pcs)
Table 30. Global Durvalumab Sales Market Share by Country/Region (2018-2023)
Table 31. Global Durvalumab Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Durvalumab Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Durvalumab Sales by Country (2018-2023) & (K Pcs)
Table 34. Americas Durvalumab Sales Market Share by Country (2018-2023)
Table 35. Americas Durvalumab Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Durvalumab Revenue Market Share by Country (2018-2023)
Table 37. Americas Durvalumab Sales by Type (2018-2023) & (K Pcs)
Table 38. Americas Durvalumab Sales by Application (2018-2023) & (K Pcs)
Table 39. APAC Durvalumab Sales by Region (2018-2023) & (K Pcs)
Table 40. APAC Durvalumab Sales Market Share by Region (2018-2023)
Table 41. APAC Durvalumab Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Durvalumab Revenue Market Share by Region (2018-2023)
Table 43. APAC Durvalumab Sales by Type (2018-2023) & (K Pcs)
Table 44. APAC Durvalumab Sales by Application (2018-2023) & (K Pcs)
Table 45. Europe Durvalumab Sales by Country (2018-2023) & (K Pcs)
Table 46. Europe Durvalumab Sales Market Share by Country (2018-2023)
Table 47. Europe Durvalumab Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Durvalumab Revenue Market Share by Country (2018-2023)
Table 49. Europe Durvalumab Sales by Type (2018-2023) & (K Pcs)
Table 50. Europe Durvalumab Sales by Application (2018-2023) & (K Pcs)
Table 51. Middle East & Africa Durvalumab Sales by Country (2018-2023) & (K Pcs)
Table 52. Middle East & Africa Durvalumab Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Durvalumab Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Durvalumab Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Durvalumab Sales by Type (2018-2023) & (K Pcs)
Table 56. Middle East & Africa Durvalumab Sales by Application (2018-2023) & (K Pcs)
Table 57. Key Market Drivers & Growth Opportunities of Durvalumab
Table 58. Key Market Challenges & Risks of Durvalumab
Table 59. Key Industry Trends of Durvalumab
Table 60. Durvalumab Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Durvalumab Distributors List
Table 63. Durvalumab Customer List
Table 64. Global Durvalumab Sales Forecast by Region (2024-2029) & (K Pcs)
Table 65. Global Durvalumab Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Durvalumab Sales Forecast by Country (2024-2029) & (K Pcs)
Table 67. Americas Durvalumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Durvalumab Sales Forecast by Region (2024-2029) & (K Pcs)
Table 69. APAC Durvalumab Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Durvalumab Sales Forecast by Country (2024-2029) & (K Pcs)
Table 71. Europe Durvalumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Durvalumab Sales Forecast by Country (2024-2029) & (K Pcs)
Table 73. Middle East & Africa Durvalumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Durvalumab Sales Forecast by Type (2024-2029) & (K Pcs)
Table 75. Global Durvalumab Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Durvalumab Sales Forecast by Application (2024-2029) & (K Pcs)
Table 77. Global Durvalumab Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Medimmune (AstraZeneca) Basic Information, Durvalumab Manufacturing Base, Sales Area and Its Competitors
Table 79. Medimmune (AstraZeneca) Durvalumab Product Portfolios and Specifications
Table 80. Medimmune (AstraZeneca) Durvalumab Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
Table 81. Medimmune (AstraZeneca) Main Business
Table 82. Medimmune (AstraZeneca) Latest Developments
Table 1. Durvalumab Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Durvalumab Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of 2.4mL Injection
Table 4. Major Players of 10mL Injection
Table 5. Global Durvalumab Sales by Type (2018-2023) & (K Pcs)
Table 6. Global Durvalumab Sales Market Share by Type (2018-2023)
Table 7. Global Durvalumab Revenue by Type (2018-2023) & ($ million)
Table 8. Global Durvalumab Revenue Market Share by Type (2018-2023)
Table 9. Global Durvalumab Sale Price by Type (2018-2023) & (USD/Pcs)
Table 10. Global Durvalumab Sales by Application (2018-2023) & (K Pcs)
Table 11. Global Durvalumab Sales Market Share by Application (2018-2023)
Table 12. Global Durvalumab Revenue by Application (2018-2023)
Table 13. Global Durvalumab Revenue Market Share by Application (2018-2023)
Table 14. Global Durvalumab Sale Price by Application (2018-2023) & (USD/Pcs)
Table 15. Global Durvalumab Sales by Company (2018-2023) & (K Pcs)
Table 16. Global Durvalumab Sales Market Share by Company (2018-2023)
Table 17. Global Durvalumab Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Durvalumab Revenue Market Share by Company (2018-2023)
Table 19. Global Durvalumab Sale Price by Company (2018-2023) & (USD/Pcs)
Table 20. Key Manufacturers Durvalumab Producing Area Distribution and Sales Area
Table 21. Players Durvalumab Products Offered
Table 22. Durvalumab Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Durvalumab Sales by Geographic Region (2018-2023) & (K Pcs)
Table 26. Global Durvalumab Sales Market Share Geographic Region (2018-2023)
Table 27. Global Durvalumab Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Durvalumab Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Durvalumab Sales by Country/Region (2018-2023) & (K Pcs)
Table 30. Global Durvalumab Sales Market Share by Country/Region (2018-2023)
Table 31. Global Durvalumab Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Durvalumab Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Durvalumab Sales by Country (2018-2023) & (K Pcs)
Table 34. Americas Durvalumab Sales Market Share by Country (2018-2023)
Table 35. Americas Durvalumab Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Durvalumab Revenue Market Share by Country (2018-2023)
Table 37. Americas Durvalumab Sales by Type (2018-2023) & (K Pcs)
Table 38. Americas Durvalumab Sales by Application (2018-2023) & (K Pcs)
Table 39. APAC Durvalumab Sales by Region (2018-2023) & (K Pcs)
Table 40. APAC Durvalumab Sales Market Share by Region (2018-2023)
Table 41. APAC Durvalumab Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Durvalumab Revenue Market Share by Region (2018-2023)
Table 43. APAC Durvalumab Sales by Type (2018-2023) & (K Pcs)
Table 44. APAC Durvalumab Sales by Application (2018-2023) & (K Pcs)
Table 45. Europe Durvalumab Sales by Country (2018-2023) & (K Pcs)
Table 46. Europe Durvalumab Sales Market Share by Country (2018-2023)
Table 47. Europe Durvalumab Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Durvalumab Revenue Market Share by Country (2018-2023)
Table 49. Europe Durvalumab Sales by Type (2018-2023) & (K Pcs)
Table 50. Europe Durvalumab Sales by Application (2018-2023) & (K Pcs)
Table 51. Middle East & Africa Durvalumab Sales by Country (2018-2023) & (K Pcs)
Table 52. Middle East & Africa Durvalumab Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Durvalumab Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Durvalumab Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Durvalumab Sales by Type (2018-2023) & (K Pcs)
Table 56. Middle East & Africa Durvalumab Sales by Application (2018-2023) & (K Pcs)
Table 57. Key Market Drivers & Growth Opportunities of Durvalumab
Table 58. Key Market Challenges & Risks of Durvalumab
Table 59. Key Industry Trends of Durvalumab
Table 60. Durvalumab Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Durvalumab Distributors List
Table 63. Durvalumab Customer List
Table 64. Global Durvalumab Sales Forecast by Region (2024-2029) & (K Pcs)
Table 65. Global Durvalumab Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Durvalumab Sales Forecast by Country (2024-2029) & (K Pcs)
Table 67. Americas Durvalumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Durvalumab Sales Forecast by Region (2024-2029) & (K Pcs)
Table 69. APAC Durvalumab Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Durvalumab Sales Forecast by Country (2024-2029) & (K Pcs)
Table 71. Europe Durvalumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Durvalumab Sales Forecast by Country (2024-2029) & (K Pcs)
Table 73. Middle East & Africa Durvalumab Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Durvalumab Sales Forecast by Type (2024-2029) & (K Pcs)
Table 75. Global Durvalumab Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Durvalumab Sales Forecast by Application (2024-2029) & (K Pcs)
Table 77. Global Durvalumab Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Medimmune (AstraZeneca) Basic Information, Durvalumab Manufacturing Base, Sales Area and Its Competitors
Table 79. Medimmune (AstraZeneca) Durvalumab Product Portfolios and Specifications
Table 80. Medimmune (AstraZeneca) Durvalumab Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023)
Table 81. Medimmune (AstraZeneca) Main Business
Table 82. Medimmune (AstraZeneca) Latest Developments
LIST OF FIGURES
Figure 1. Picture of Durvalumab
Figure 2. Durvalumab Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Durvalumab Sales Growth Rate 2018-2029 (K Pcs)
Figure 7. Global Durvalumab Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Durvalumab Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of 2.4mL Injection
Figure 10. Product Picture of 10mL Injection
Figure 11. Global Durvalumab Sales Market Share by Type in 2022
Figure 12. Global Durvalumab Revenue Market Share by Type (2018-2023)
Figure 13. Durvalumab Consumed in Locally Advanced Urothelial Carcinoma
Figure 14. Global Durvalumab Market: Locally Advanced Urothelial Carcinoma (2018-2023) & (K Pcs)
Figure 15. Durvalumab Consumed in Metastatic Urothelial Carcinoma
Figure 16. Global Durvalumab Market: Metastatic Urothelial Carcinoma (2018-2023) & (K Pcs)
Figure 17. Durvalumab Consumed in Other
Figure 18. Global Durvalumab Market: Other (2018-2023) & (K Pcs)
Figure 19. Global Durvalumab Sales Market Share by Application (2022)
Figure 20. Global Durvalumab Revenue Market Share by Application in 2022
Figure 21. Durvalumab Sales Market by Company in 2022 (K Pcs)
Figure 22. Global Durvalumab Sales Market Share by Company in 2022
Figure 23. Durvalumab Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Durvalumab Revenue Market Share by Company in 2022
Figure 25. Global Durvalumab Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Durvalumab Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Durvalumab Sales 2018-2023 (K Pcs)
Figure 28. Americas Durvalumab Revenue 2018-2023 ($ Millions)
Figure 29. APAC Durvalumab Sales 2018-2023 (K Pcs)
Figure 30. APAC Durvalumab Revenue 2018-2023 ($ Millions)
Figure 31. Europe Durvalumab Sales 2018-2023 (K Pcs)
Figure 32. Europe Durvalumab Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Durvalumab Sales 2018-2023 (K Pcs)
Figure 34. Middle East & Africa Durvalumab Revenue 2018-2023 ($ Millions)
Figure 35. Americas Durvalumab Sales Market Share by Country in 2022
Figure 36. Americas Durvalumab Revenue Market Share by Country in 2022
Figure 37. Americas Durvalumab Sales Market Share by Type (2018-2023)
Figure 38. Americas Durvalumab Sales Market Share by Application (2018-2023)
Figure 39. United States Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Durvalumab Sales Market Share by Region in 2022
Figure 44. APAC Durvalumab Revenue Market Share by Regions in 2022
Figure 45. APAC Durvalumab Sales Market Share by Type (2018-2023)
Figure 46. APAC Durvalumab Sales Market Share by Application (2018-2023)
Figure 47. China Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Durvalumab Sales Market Share by Country in 2022
Figure 55. Europe Durvalumab Revenue Market Share by Country in 2022
Figure 56. Europe Durvalumab Sales Market Share by Type (2018-2023)
Figure 57. Europe Durvalumab Sales Market Share by Application (2018-2023)
Figure 58. Germany Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Durvalumab Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Durvalumab Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Durvalumab Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Durvalumab Sales Market Share by Application (2018-2023)
Figure 67. Egypt Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Durvalumab in 2022
Figure 73. Manufacturing Process Analysis of Durvalumab
Figure 74. Industry Chain Structure of Durvalumab
Figure 75. Channels of Distribution
Figure 76. Global Durvalumab Sales Market Forecast by Region (2024-2029)
Figure 77. Global Durvalumab Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Durvalumab Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Durvalumab Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Durvalumab Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Durvalumab Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Durvalumab
Figure 2. Durvalumab Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Durvalumab Sales Growth Rate 2018-2029 (K Pcs)
Figure 7. Global Durvalumab Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Durvalumab Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of 2.4mL Injection
Figure 10. Product Picture of 10mL Injection
Figure 11. Global Durvalumab Sales Market Share by Type in 2022
Figure 12. Global Durvalumab Revenue Market Share by Type (2018-2023)
Figure 13. Durvalumab Consumed in Locally Advanced Urothelial Carcinoma
Figure 14. Global Durvalumab Market: Locally Advanced Urothelial Carcinoma (2018-2023) & (K Pcs)
Figure 15. Durvalumab Consumed in Metastatic Urothelial Carcinoma
Figure 16. Global Durvalumab Market: Metastatic Urothelial Carcinoma (2018-2023) & (K Pcs)
Figure 17. Durvalumab Consumed in Other
Figure 18. Global Durvalumab Market: Other (2018-2023) & (K Pcs)
Figure 19. Global Durvalumab Sales Market Share by Application (2022)
Figure 20. Global Durvalumab Revenue Market Share by Application in 2022
Figure 21. Durvalumab Sales Market by Company in 2022 (K Pcs)
Figure 22. Global Durvalumab Sales Market Share by Company in 2022
Figure 23. Durvalumab Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Durvalumab Revenue Market Share by Company in 2022
Figure 25. Global Durvalumab Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Durvalumab Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Durvalumab Sales 2018-2023 (K Pcs)
Figure 28. Americas Durvalumab Revenue 2018-2023 ($ Millions)
Figure 29. APAC Durvalumab Sales 2018-2023 (K Pcs)
Figure 30. APAC Durvalumab Revenue 2018-2023 ($ Millions)
Figure 31. Europe Durvalumab Sales 2018-2023 (K Pcs)
Figure 32. Europe Durvalumab Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Durvalumab Sales 2018-2023 (K Pcs)
Figure 34. Middle East & Africa Durvalumab Revenue 2018-2023 ($ Millions)
Figure 35. Americas Durvalumab Sales Market Share by Country in 2022
Figure 36. Americas Durvalumab Revenue Market Share by Country in 2022
Figure 37. Americas Durvalumab Sales Market Share by Type (2018-2023)
Figure 38. Americas Durvalumab Sales Market Share by Application (2018-2023)
Figure 39. United States Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Durvalumab Sales Market Share by Region in 2022
Figure 44. APAC Durvalumab Revenue Market Share by Regions in 2022
Figure 45. APAC Durvalumab Sales Market Share by Type (2018-2023)
Figure 46. APAC Durvalumab Sales Market Share by Application (2018-2023)
Figure 47. China Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Durvalumab Sales Market Share by Country in 2022
Figure 55. Europe Durvalumab Revenue Market Share by Country in 2022
Figure 56. Europe Durvalumab Sales Market Share by Type (2018-2023)
Figure 57. Europe Durvalumab Sales Market Share by Application (2018-2023)
Figure 58. Germany Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Durvalumab Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Durvalumab Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Durvalumab Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Durvalumab Sales Market Share by Application (2018-2023)
Figure 67. Egypt Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Durvalumab Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Durvalumab in 2022
Figure 73. Manufacturing Process Analysis of Durvalumab
Figure 74. Industry Chain Structure of Durvalumab
Figure 75. Channels of Distribution
Figure 76. Global Durvalumab Sales Market Forecast by Region (2024-2029)
Figure 77. Global Durvalumab Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Durvalumab Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Durvalumab Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Durvalumab Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Durvalumab Revenue Market Share Forecast by Application (2024-2029)
